Indegene

Indegene P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Indegene (INDGN.NS) as of Oct 21, 2026 is 17.15. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 25.75 — a change of -33.39% (lower).

P/CF

17.15

YoY

-33.39%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Indegene is 2026 17.15 . P/CF (Price-to-Cash-Flow Ratio) of Indegene was 2025 25.75 . It decreases by -33.39% lower compared to the previous year.

The Indegene P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2020
510.88 INR
Jan 1, 2021
66.14 INR
Jan 1, 2022
38.31 INR
Jan 1, 2023
87.38 INR
Jan 1, 2024
22.41 INR
Jan 1, 2025
25.75 INR
Jan 1, 2026
17.15 INR
The Indegene P/CF history
YEARP/CFYoY
17.15-33.39%
25.75+14.89%
22.41-74.35%
87.38+128.11%
38.31-42.08%
66.14-87.05%
510.88—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Indegene Stock analysis

What does Indegene do? Indegene Ltd generates revenue by providing digital-led commercialization services to life sciences companies, including biopharmaceutical, emerging biotech, and medical devices firms. The company assists these clients with drug development, clinical trials, regulatory submissions, pharmacovigilance, complaints management, and the sales and marketing of their products. This comprehensive support structure allows Indegene to serve as a key partner in the end-to-end commercialization process for its diverse client base within the life sciences sector. The company monetizes its offerings through specialized solution segments such as Omnichannel Activation, which helps life sciences companies leverage a digital first approach for optimizing the last-mile promotion of biopharmaceutical products and medical devices to healthcare professionals across multiple channels. Additionally, Enterprise Commercial Solutions primarily involves assisting life sciences companies with their digital marketing operations, further expanding the company's service portfolio and revenue streams. Revenue is also derived from Enterprise Medical Solutions, where Indegene establishes centers of excellence to consolidate large scale regulatory and medical operations for its clients. The company rounds out its business model by offering enterprise clinical solutions and consultancy services, ensuring a holistic service delivery model that addresses various operational needs of its customers in the life sciences industry. Indegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Indegene stock

P/CF (Price-to-Cash-Flow Ratio) of Indegene is 17.15 in 2026.

P/CF (Price-to-Cash-Flow Ratio) of Indegene changed from 25.75 to 17.15, representing a -33.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Indegene since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Indegene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Indegene

All Key Metrics — Indegene